Prolia denied as duplicate or overlapping therapy by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for prolia are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denies Prolia as Duplicate Therapy

UnitedHealthcare may issue a duplicate-therapy denial for Prolia (denosumab) when its records show that another bone-modifying or osteoporosis treatment — such as a bisphosphonate or another antiresorptive agent — has recently been dispensed or remains active on the patient's medication profile. The plan's position is that two agents addressing the same clinical indication represent redundant therapy. These denials are often triggered by automated pharmacy claims review rather than a clinician's individualized assessment of your case.

## Why This Denial Is Appealable

The duplicate-therapy flag does not account for the clinical reasons a prescriber may transition a patient from one agent to another, prescribe agents with different mechanisms sequentially, or use agents for distinct indications (for example, Prolia is also approved for bone loss in certain oncology settings, which is a separate clinical context from osteoporosis). If the prior agent has been discontinued, if the patient experienced an inadequate response or clinical event prompting the change, or if the two agents are prescribed for non-overlapping indications, the duplicate-therapy premise is factually incorrect and the denial should be overturned.

## Federal Appeal Framework

• Internal appeal (ACA §2719): Request a full internal appeal. Ask the plan in writing to identify the specific other agent it considers duplicative and the policy basis for the determination.
• ERISA §503: For employer-sponsored plans, ERISA entitles you to the complete claims file, the specific criteria applied, and the identity of the clinical reviewer.
• External review: After exhausting internal appeals, ACA §2719 external review by an independent organization is available. External reviewers regularly reverse duplicate-therapy denials when the prescriber documents distinct clinical rationale.
• Timeline: External review requests are typically due within four months of the final adverse internal decision. Expedited review (72 hours) is available when delay seriously jeopardizes health.

## Documents to Gather

• Medication reconciliation: A current, dated medication list from the prescriber confirming which bone-modifying agents are actually active, which have been discontinued, and when.
• Prescriber letter: A letter from the treating clinician explaining why Prolia is being prescribed, the distinct clinical rationale versus any prior agent, and — if transitioning — the clinical reason the prior agent was stopped.
• Diagnosis and indication documentation: Chart notes confirming the specific indication for which Prolia is ordered, particularly if the indication differs from the condition treated by any prior agent.
• UHC policy: Obtain UHC's published coverage policy for Prolia and its duplicate-therapy criteria. Confirm exactly which concurrent or recent therapies trigger the flag.

## Criteria-Mapping Structure

In your appeal, name the specific agent UHC identified as duplicative, then document precisely why the situation is not clinically duplicative: different indication, discontinued prior agent with documented reason, or distinct mechanism for a complex patient. Map each policy criterion to a specific chart fact or prescriber statement. A clear, factual rebuttal of the duplicate premise — rather than a general medical-necessity argument — is the most efficient path to reversal.